Section Arrow
JBIO.NASDAQ
- Jade Biosciences Inc
Quotes are at least 15-min delayed:2026/04/10 21:25 EDT
Regular Hours
Last
 17.89
-0.34 (-1.87%)
Day High 
18.485 
Prev. Close
18.23 
1-M High
18.375 
Volume 
654.49K 
Bid
17.11
Ask
17.7
Day Low
17.365 
Open
18.32 
1-M Low
12.91 
Market Cap 
899.04M 
Currency 美元 
P/E -- 
%Yield 89.55 
10-SMA 15.37 
20-SMA 14.63 
50-SMA 14.69 
52-W High 100.1 
52-W Low 6.565 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.19/-2.09
Enterprise Value
899.76M
Balance Sheet
Book Value Per Share
6.74
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CUECue Biopharma0.5019+0.209+71.36%-- 
QNCXQuince Therapeutics0.1363+0.0126+10.19%-- 
VRAXVirax Biolabs Group Limited0.1041-0.0308-22.83%-- 
ZNTLZentalis Pharmaceuticals6.61+2.19+49.55%-- 
IOVAIovance Biotherapeutics3.7-0.31-7.73%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.